Merck hikes dividend 11%; Parallel trade triggers U.K. drug shortages;

 @FiercePharma: Pfizer has big plans for Prevenar in China: It's aiming to penetrate rural areas as the vax market grows-Reuters. News | Follow @FiercePharma 

> Merck ($MRK) raised its dividend by 11% to 42 cents per share in its first payout hike since 2004, sending shares up by 2% in early trading. News | Report

> Parallel trade is depleting U.K. supplies of some drugs, with 80% of surveyed pharmacists saying they couldn't fill certain prescriptions because of shortages. Story

> Generics maker Stada posted a loss for the first nine months of the year, because of write-downs on its Serbian business and heightened competition in Germany. Item

> GlaxoSmithKline ($GSK) bought back 850,000 of its shares for prices between 1367 and 1394 pence. Article

> India's Lupin will build up in Japan, planning to grow more than 14% annually in that market. News

> UCB released new positive data on its rheumatoid arthritis drug Cimzia, including a study showing that response by the 12th week of treatment would predict longer-term outcomes. Item

> Wolters Kluwer agreed to sell its pharma marketing and publishing services to Spring Science+Business Media. Story

> Belleville, NJ, said it would refund $1.7 million in property taxes on Roche Diagnostics' site, for overpayments made from 2007 to 2011. Report

> Baxter International ($BAX) said it wrapped up its $380 million acquisition of Baxa, a Colorado pharmacy technology company. Baxter release

Biotech News

 @FierceBiotech:  Sanofi drug REGN727 packs anti-cholesterol punch in Ph2 trials. News | Follow @FierceBiotech

 @JohnCFierce: Merck gets 2 CRLs, from FDA, buries them in a 62-page filing. Somebody didn't get the memo on transparency. Report | Follow @JohnCFierce

 @MaureenFierce: Cervical cancer vaccines may cut need for cancer screenings. Item | Follow @MaureenFierce

> FDA deals Merck two R&D setbacks with pair of CRLs. Item

> Sanofi drug packs anti-cholesterol punch in Ph2 trials. Report 

Vaccines News

> Nabi explores options after NicVAX flunks trial. News

> Researchers find two potential lupus vax treatments. Item

> Gates backs microneedle polio vaccine work. Article

> PANVAC for breast, ovarian cancer shows early promise. Report

> Study: Cervarix could cut need for cancer screenings. News

Manufacturing News

> Chinese pharma exec gets suspended death sentence. Story

> Genentech, INIS demonstrate art of FDA response. Report

> International Isotopes gets FDA warning. Article

> OxyContin abuse overshadows formulation fix. News

> Manufacturing embraces IT as some drugmakers minimize R&D focus. Article

> KV crows over Makena purity as FDA checks claim. Story

 And Finally... A new approach to brain monitoring finds signs of awareness in "vegetative" patients. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.